The Cancer Letter

Inside information on cancer research and drug development

In Brief

Michael Rosen named chief communications officer at Pancreatic Cancer Action Network

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Michael Rosen was named chief communications officer at the Pancreatic Cancer Action Network.

One of Rosen’s key roles will be increasing awareness about the organization’s ground breaking research and clinical initiatives like Precision Promise, a revolutionary clinical trial that will dramatically accelerate progress and bring promising therapies to patients faster.

Most recently, Rosen served as executive vice president of marketing and communications for the Mental Health Association of New York City, where he managed all marketing, communications strategies and development.

Between 2013 and 2016, Rosen led strategic communications for Autism Speaks, the world’s largest autism advocacy organization.

Prior to entering the nonprofit sector, Rosen was the executive producer first of The Saturday Early Show and then CBS This Morning Saturday. At ABC News, Rosen was second in charge for the network’s Peabody Award-winning coverage of 9/11, and covered the war in Kosovo on location. Rosen has won three Emmy Awards, two Peabody Awards and four DuPont Awards.

Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthConversation with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

By Jacquelyn Cobb
Guest Editorial

Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

By Harpreet Singh
Sponsored

Advancing pediatric oncology and survivorship: A research vision at City of Hope

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.
By Saro Armenian
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account